These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19367024)

  • 1. [Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
    Tahara M; Shibata A; Yamaguchi S; Hamada Y
    Nihon Yakurigaku Zasshi; 2009 Apr; 133(4):215-26. PubMed ID: 19367024
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunitinib maleate.
    Atkins M; Jones CA; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Apr; 5(4):279-80. PubMed ID: 16628834
    [No Abstract]   [Full Text] [Related]  

  • 3. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
    Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
    Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
    Mansueto G; Longo F
    Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
    [No Abstract]   [Full Text] [Related]  

  • 8. Sunitinib.
    Heng DY; Kollmannsberger C
    Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib in solid tumors.
    Gan HK; Seruga B; Knox JJ
    Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
    Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
    Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma].
    Vollmer H
    Med Monatsschr Pharm; 2006 Oct; 29(10):386-7. PubMed ID: 17058904
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC; Pulido EG; Guillén-Ponce C
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
    Gyawali B; Ando Y
    Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
    [No Abstract]   [Full Text] [Related]  

  • 20. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
    Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.